急性冠脉综合征患者血清胱抑素C水平与冠脉病变程度的关系
Association of Serum Cystatin C Levels with Disease Severity in Patients with Acute Coronary Syndrome
DOI: 10.12677/ACM.2021.113121, PDF,   
作者: 刘雅娟:青岛大学医学院,山东 青岛;王其新*:青岛大学附属医院急诊科,山东 青岛
关键词: 急性冠脉综合征胱抑素C尿酸Gensini评分Acute Coronary Syndrome Cystatin C Uric Acid Gensini Scores
摘要: 目的:探讨血清胱抑素C水平(CysC)与急性冠脉综合征(Acute coronary syndrome, ACS)患者冠脉病变程度的关系。方法:选取经冠状动脉造影检查确诊ACS的253例患者作为观察组,40例同期经冠脉造影检查排除冠心病的患者作为对照组。入院后检测患者次日晨起空腹血清胱抑素C水平,将ACS患者血清CysC水平与Gensini评分作相关性分析。结果:随着冠脉病变程度的增加,血清CysC、尿酸(UA)水平逐渐升高,组间比较差异均有统计学意义(P < 0.01)。血清CysC、UA水平与ACS患者Gensini评分呈正相关(P < 0.05),是影响Gensini评分的危险因素(P < 0.05)。结论:ACS患者血清CysC、UA水平与冠脉病变严重程度相关,是使冠脉病变程度加重的危险因素。对ACS患者进行监测和早期干预治疗,有助于预防心血管不良事件的发生。
Abstract: Objective: To investigate the correlation between coronary artery lesion score and serum cystatin C (CysC) level in acute coronary syndrome (ACS). Methods: 253 patients were admitted from January 2019 to December 2019 with ACS and 39 patients without ACS (the control group) were enrolled in the study. All subjects underwent coronary angiography. ACS patients were divided into the low score group, the middle score group and the high score group by coronary artery stenosis score (Gensini); patients in the control group were excluded with coronary artery disease by coronary angiography. Serum CysC levels were measured within 24 h after admission. The correlation between CysC level and Gensini score was compared. Results: With the increase of severity of coronary artery disease, the levels of CysC and uric acid (UA) were increased. The difference between groups was highly statistically significant (P < 0.01). Logistic regression analysis showed that Gensini scores were positively correlated with levels of CysC and UA (P < 0.05). High serum CysC and UA levels were independent risk factors for high Gensini scores. Conclusion: The levels of serum CysC and UA in ACS patients are related to the severity of coronary artery lesion, and are the risk factors of the severity of coronary artery lesion. In clinical work, monitoring of the above indicators and early intervention therapy for ACS patients were of great clinical significance for preventing the occurrence of acute coronary events.
文章引用:刘雅娟, 王其新. 急性冠脉综合征患者血清胱抑素C水平与冠脉病变程度的关系[J]. 临床医学进展, 2021, 11(3): 856-861. https://doi.org/10.12677/ACM.2021.113121

参考文献

[1] Zhang, J., Wu, X., Gao, P. and Yan, P. (2017) Correlations of Serum Cystatin C and Glomerular Filtration Rate with Vascular Lesions and Severity in Acute Coronary Syndrome. BMC Cardiovascular Disorders, 17, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[2] Virani, S.S., Alonso, A., Benjamin, E.J., Bittencourt, M.S., Callaway, C.W., Carson, A.P., et al. (2020) Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. Circulation, 141, e139-e596. [Google Scholar] [CrossRef
[3] Tan, Z., Li, L., Ma, Y. and Geng, X.B. (2019) Clinical Significance of Cys-C and hs-CRP in Coronary Heart Disease Patients Undergoing Percutaneous Coronary Intervention. Brazilian Journal of Cardiovascular Surgery, 34, 17-21. [Google Scholar] [CrossRef] [PubMed]
[4] Shlipak, M.G., Sarnak, M.J., Katz, R., Fried, L.F., Seliger, S.L., Newman, A.B., et al. (2005) Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons. The New England Journal of Medicine, 352, 2049-2060. [Google Scholar] [CrossRef
[5] Shlipak, M.G., Sarnak, M.J., Katz, R., Fried, L.F., Seliger, S., Newman, A., et al. (2005) Cystatin-C and Mortality in Elderly Persons with Heart Failure. Journal of the American College of Cardiology, 45, 268-271. [Google Scholar] [CrossRef] [PubMed]
[6] Coll, E., Botey, A., Alvarez, L., Poch, E., Quintó, L., Saurina, A., et al. (2000) Serum Cystatin C as a New Marker for Noninvasive Estimation of Glomerular Filtration Rate and as a Marker for Early Renal Impairment. American Journal of Kidney Diseases, 36, 29-34. [Google Scholar] [CrossRef] [PubMed]
[7] Abid, L., Charfeddine, S., Kammoun, S., Turki, M. and Ayedi, F. (2016) Cystatin C: A Prognostic Marker after Myocardial Infarction in Patients without Chronic Kidney Disease. Journal of the Saudi Heart Association, 28, 144-151. [Google Scholar] [CrossRef] [PubMed]
[8] Maahs, D.M., Ogden, L.G., Kretowski, A., Snell-Bergeon, J.K., Kinney, G.L., Berl, T., et al. (2007) Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals with Type 1 Diabetes. Diabetes, 56, 2774-2779. [Google Scholar] [CrossRef] [PubMed]
[9] Knight, E.L., Verhave, J.C., Spiegelman, D., Hillege, H.L., De Zeeuw, D., Curhan, G.C., et al. (2004) Factors Influencing Serum Cystatin C Levels Other than Renal Function and the Impact on Renal Function Measurement. Kidney International, 65, 1416-1421. [Google Scholar] [CrossRef] [PubMed]
[10] Ge, C., Ren, F., Lu, S., Ji, F., Chen, X. and Wu, X. (2009) Clinical Prognostic Significance of Plasma Cystatin C Levels among Patients with Acute Coronary Syndrome. Clinical Cardiology, 32, 644-648. [Google Scholar] [CrossRef] [PubMed]
[11] Levine, G.N., Bates, E.R., Bittl, J.A., Brindis, R.G., Fihn, S.D., Fleisher, L.A., et al. (2016) 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation, 134, e123-e155. [Google Scholar] [CrossRef
[12] Amsterdam, E.A., Wenger, N.K., Brindis, R.G., Casey Jr., D.E., Ganiats, T.G., Holmes Jr., D.R., et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 140, e344-e426. [Google Scholar] [CrossRef
[13] O’gara, P.T., Kushner, F.G., Ascheim, D.D., Casey Jr., D.E., Chung, M.K., de Lemos, J.A., et al. (2013) 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61, 485-510. [Google Scholar] [CrossRef] [PubMed]
[14] Rampidis, G.P., Benetos, G., Benz, D.C., Giannopoulos, A.A. and Buechel, R.R. (2019) A Guide for Gensini Score Calculation. Atherosclerosis, 287, 181-183. [Google Scholar] [CrossRef] [PubMed]
[15] 中国医师协会急诊医师分会, 国家卫健委能力建设与继续教育中心急诊学专家委员会, 中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019) [J]. 中华急诊医学杂志, 2019, 28(4): 421-428.
[16] Van Holten, T.C., Waanders, L.F., De Groot, P.G., Vissers, J., Hoefer, I.E., Pasterkamp, G., et al. (2013) Circulating Biomarkers for Predicting Cardiovascular Disease Risk; A Systematic Review and Comprehensive Overview of Meta-Analyses. PLoS ONE, 8, e62080. [Google Scholar] [CrossRef] [PubMed]
[17] Taglieri, N., Koenig, W. and Kaski, J.C. (2009) Cystatin C and Cardiovascular Risk. Clinical Chemistry, 55, 1932-1943. [Google Scholar] [CrossRef] [PubMed]
[18] Hamzic-Mehmedbasic, A. (2016) Inflammatory Cytokines as Risk Factors for Mortality after Acute Cardiac Events. Medical Archives, 70, 252-255. [Google Scholar] [CrossRef] [PubMed]
[19] Hoke, M., Amighi, J., Mlekusch, W., Schlager, O., Exner, M., Sabeti, S., et al. (2010) Cystatin C and the Risk for Cardiovascular Events in Patients with Asymptomatic Carotid Atherosclerosis. Stroke, 41, 674-679. [Google Scholar] [CrossRef
[20] Huang, Q., Shen, W., Li, J., Luo, X., Shi, H., Yan, P., et al. (2019) Association of Serum Cystatin C Levels with Acute Coronary Syndrome in Patients of Advanced Age. Journal of International Medical Research, 47, 1987-1997. [Google Scholar] [CrossRef
[21] Negrusz-Kawecka, M., Poreba, R., Hulok, A., Sciborski, K., Marczak, J. and Bańkowski, T. (2014) Evaluation of the Significance of Cystatin C Levels in Patients Suffering from Coronary Artery Disease. Advances in Clinical and Experimental Medicine, 23, 551-558.
[22] Alhusseiny, A.H., Al-Nimer, M.S. and Al-Neamy, S.I. (2015) Assessment of Serum Cystatin C Levels in Newly Diagnosed Acute Myocardial Infarction at the Onset and at the Time of Hospital Discharge. Cardiology Research, 6, 226-231. http://dx.doi.org/10.14740/cr377w [Google Scholar] [CrossRef] [PubMed]
[23] Lodh, M., Parida, A., Sanyal, J. and Ganguly, A. (2013) Cystatin C in Acute Coronary Syndrome. International Federation of Clinical Chemistry and Laboratory Medicine, 24, 61-67.